2020c), and also coprescription of lopinavir and rotinavir are being tested in patients around the world. to treat patients suffering from COVID-19 pneumonia utilizing MSCs. pneumonia, and Chlamydia-related pneumonia, and other coronavirus infections (de Wit et al. 2016; Malainou and Herold 2019). The incubation period regarding the incubation period of SARS and MERS viruses, as well as the available traveling data, is approximately 2C14?days (median of 5?days) (Li et al. 2020a) after infection. Studies have also shown that the incubation period of patients with lesser exposure to the infection sources turns out to be longer (Leung 2020), with a maximum of 8?weeks (Backer et al. 2020). However, as the mean interval (3C8?days) shows up earlier than the end of incubation, the carriers are contagious before the presentation of symptoms (Gentile and Sterodimas 2020a). Symptoms occur after 4C6?days PROTAC ERRα Degrader-1 of incubation, including fever, cough, shortness of breath (Chen et al. 2020b), anosmia, bone pain, impaired taste, dyspnea, breathing difficulties, malaise, leukopenia, thrombocytopenia, lymphopenia, along with the elevated levels of neutrophils (Chan et al. 2020), C-reactive protein (CRP), and increased titers PROTAC ERRα Degrader-1 of IgG and IgM antibodies (Zhou PROTAC ERRα Degrader-1 et al. 2020a) in the prodromal phase (Chan et al. 2020; Chen et al. 2020b; Huang et al. 2020b). Raised levels of pro-inflammatory and anti-inflammatory cytokines (CKs), such as interleukin-10 (IL-10) have also been reported in plasma, which might be associated with disease severity (Huang et al. 2020b; Wong et al. 2004). Some patients have also developed nausea before the fever, headache or hemoptysis (Guan et al. 2020), sneeze, confusion, chest pain (Rothe et al. 2020; Van Cuong et al. 2020), chills, fatigue or myalgia, several patchy shadows in both lungs based on chest radiography imaging observations (Xu et al. 2020b), elevation in serum levels of either of the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) enzymes (Chen et al. 2020b; Huang et al. 2020b), gastrointestinal symptoms such as diarrhea (Zhu et al. 2019) and upper respiratory symptoms such as rhinorrhea. However, older adults, specially males with a median age of 59 (Chen et al. 2020b), persons with underlying health conditions, such as obesity, hypertension, respiratory disease, endocrine metabolic disease, cardiovascular disease, chronic kidney disease, or diabetes mellitus, as well as persons with compromised immune systems are likely to develop more severe symptoms (Novel 2020). According to WHO, not all COVID-19 patients Pdgfd develop the symptoms as mentioned earlier and roughly 1 out of 6 among the infected develop difficulty breathing, thus approximately 80% of the infected recover. Newborn babies from the infected mothers may also be subject to the infection. According to two reports of 18 infected mothers in the third trimester, all neonates tested negative for the PROTAC ERRα Degrader-1 COVID-19. Still a baby tested positive who was born from a mother suffering from the COVID-19 in London (Chamseddine et al. 2020). Complications include acute lung injury (ALI), ARDS, characterized by osmotic gradient disruption and impaired alveolar fluid clearance (AFC), interstitial edema, acute heart damage, following the inflammation in the cardiac muscles, resulting in myocardium degeneration, occasional necrosis, and cardiac arrest. Besides, acute renal injury is reported, as proteins or blood is detected in the urine of half of the patients, due to the exudation in the glomerulus leading to kidney failure, and no treatment choice but dialysis or kidney transplantation. Other complications include reduction and damage of spermatogenic cells in testis, brain congestion, pancreatic islet cell degeneration,.